These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 30216501)
1. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma. Chen C; Han G; Li Y; Yue Z; Wang L; Liu J J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501 [TBL] [Abstract][Full Text] [Related]
2. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
3. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
4. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
5. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243 [TBL] [Abstract][Full Text] [Related]
6. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181 [TBL] [Abstract][Full Text] [Related]
7. FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1. Chen C; Liu Y; Wang H; Zhang X; Shi Y; Chen J J Zhejiang Univ Sci B; 2023 Aug; 24(8):698-710. PubMed ID: 37551556 [TBL] [Abstract][Full Text] [Related]
8. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. Li Y; Wang X; Xu T; Xu F; Chen T; Li Z; Wang Y; Chen H; Ming J; Cai J; Jiang C; Meng X Cancer Lett; 2024 Aug; 598():217107. PubMed ID: 38992489 [TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970 [No Abstract] [Full Text] [Related]
10. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways. Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459 [TBL] [Abstract][Full Text] [Related]
11. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397 [TBL] [Abstract][Full Text] [Related]
12. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance. Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184 [TBL] [Abstract][Full Text] [Related]
13. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway. Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987 [TBL] [Abstract][Full Text] [Related]
14. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966 [TBL] [Abstract][Full Text] [Related]
15. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis. Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242 [TBL] [Abstract][Full Text] [Related]
17. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma. Chai Y; Wang C; Liu W; Fan Y; Zhang Y J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818 [TBL] [Abstract][Full Text] [Related]
18. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977 [TBL] [Abstract][Full Text] [Related]
20. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]